GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-04-15|

SK Biopharma Teams Up with Targeted Protein Degrader Ubix

by Joy Lin
Share To

SK Biopharmaceuticals has announced that it will collaborate with fellow South Korea biotech Ubix Therapeutics to develop targeted protein degraders against cancer. The news comes as SK Biopharma is looking to expand its CNS and oncology portfolio. 

Under the deal, Ubix will use its Degraducer platform to enable targeted protein degradation while SK Biopharma brings their drug development skills to the table. 

SK Biopharma can opt for exclusive rights to candidates after both companies clear early clinical trials. Ubix will receive an undisclosed upfront payment and milestones, as well as a slice of the profits following commercialization. 

Related Article: Bioplus Interphex 2021: CDMOs- The Manufacturing Hub for the Next Generation of Therapeutics

 

Targeted Protein Degradation 

 

Ubix’s Degraducer technology works by utilizing the ubiquitin-proteasome system, an intracellular degradation system. Candidates are bifunctional molecules consisting of a ligand, which binds the target protein, and a binder that binds to E3 ubiquitin ligase. The molecules bring targets close to the E3 ligase, making ubiquitination much more likely. The ubiquitinated targets are then degraded by the proteasome complex. 

Last June, Ubix partnered with Debiopharm, a Swiss-based biopharma to develop an anti-cancer modality called antibody Degraducer conjugates. The modality combines Ubix’s Degraducer molecule with Debiopharm’s antibody drug conjugate linker and a therapeutic antibody to improve drug targeting and synergy on tumor cells. 

There has been a steady flow of interest and investment in targeted protein degraders. Celeris, a young biotech founded in 2020, recently managed to secure a development contract with Boehringer Ingelheim after a similar deal with Merck (also known as MSD outside the US and Canada). Other companies working in the space include Kymera Therapeutics, Orum Therapeutics and Plexium.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals
2024-09-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
R&D
Promising CHIP Protein Could Act as ‘Molecular Switch’ to Longevity
2022-09-21
LATEST
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top